当前位置: 首页 >> 检索结果
181. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
作者: Vinod Chandran.;Désirée van der Heijde.;Roy M Fleischmann.;Eric Lespessailles.;Philip S Helliwell.;Hideto Kameda.;Ruben Burgos-Vargas.;Janelle S Erickson.;Suchitrita S Rathmann.;Aubrey Trevelin Sprabery.;Julie A Birt.;Catherine L Shuler.;Gaia Gallo.
来源: Rheumatology (Oxford). 2020年59卷10期2774-2784页
The aim was to assess the safety and efficacy of up to 156 weeks of ixekizumab (an IL-17A antagonist) treatment in PsA patients.
182. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis.
作者: Ulf Sundin.;Anna-Birgitte Aga.;Øivind Skare.;Lena B Nordberg.;Till Uhlig.;Hilde B Hammer.;Désirée van der Heijde.;Tore K Kvien.;Siri Lillegraven.;Espen A Haavardsholm.; .
来源: Rheumatology (Oxford). 2020年59卷9期2550-2555页
To investigate whether an ultrasound-guided treat-to-target strategy for early RA would lead to reduced MRI inflammation or less structural damage progression compared with a conventional treat-to-target strategy.
183. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
作者: Yoshikazu Nakaoka.;Mitsuaki Isobe.;Yoshiya Tanaka.;Tomonori Ishii.;Seido Ooka.;Hiroaki Niiro.;Naoto Tamura.;Shogo Banno.;Hajime Yoshifuji.;Yasushi Sakata.;Atsushi Kawakami.;Tatsuya Atsumi.;Shunsuke Furuta.;Hitoshi Kohsaka.;Katsuya Suzuki.;Ryoki Hara.;Yasuhiro Maejima.;Hiroshi Tsukamoto.;Yoshinari Takasaki.;Katsuhisa Yamashita.;Norihiro Okada.;Shinji Yamakido.;Syuji Takei.;Shumpei Yokota.;Norihiro Nishimoto.
来源: Rheumatology (Oxford). 2020年59卷9期2427-2434页
To investigate the long-term efficacy and safety of the IL-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK).
184. Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
作者: Lisa K Stamp.;Peter Chapman.;Christopher Frampton.;Stephen B Duffull.;Jill Drake.;Yuqing Zhang.;Tuhina Neogi.
来源: Rheumatology (Oxford). 2020年59卷9期2374-2380页
Cherry concentrate has been suggested to reduce serum urate (SU) and gout flares. The aims of this study were to determine the magnitude of the effect of tart cherry concentrate on SU in people with gout, the most effective dose of tart cherry concentrate for lowering SU, and adverse effects.
185. Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.
作者: Maxime M A Verhoeven.;Janneke Tekstra.;Paco M J Welsing.;Attila Pethö-Schramm.;Michelle E A Borm.;George A W Bruyn.;Reinhard Bos.;Ed N Griep.;Ruth Klaasen.;Jacob M van Laar.;Floris P J G Lafeber.;Johannes W J Bijlsma.;Marjolein J H de Hair.;Johannes W G Jacobs.
来源: Rheumatology (Oxford). 2020年59卷9期2325-2333页
U-Act-Early was a 2-year, randomized placebo controlled, double-blind trial, in which DMARD-naïve early RA patients were treated to the target of sustained remission (SR). Two strategies initiating tocilizumab (TCZ), with and without methotrexate (MTX), were more effective than a strategy initiating MTX. The aim of the current study was to determine longer-term effectiveness in daily clinical practice.
186. Is radiographic progression a downside of stopping TNF-inhibitor in RA patients with low disease activity, if this is followed by flare? A sub-study of the POET-US trial.
作者: Femke B G Lamers-Karnebeek.;Jolanda J Luime.;Tim L Jansen.;Piet L C M van Riel.;Johannes W G Jacobs.
来源: Rheumatology (Oxford). 2020年59卷5期1170-1171页 187. An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
作者: Janet Pope.;Emmanouil Rampakakis.;Julie Vaillancourt.;Louis Bessette.;Juris Lazovskis.;Boulos Haraoui.;John S Sampalis.
来源: Rheumatology (Oxford). 2020年59卷7期1522-1528页
The objective of this trial was to compare effectiveness of certolizumab pegol added to conventional synthetic DMARDs (csDMARDs) in RA patients, followed by continuing vs discontinuing background csDMARDs after treatment response.
188. A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis.
作者: Cynthia Aranow.;John Cush.;Marcy B Bolster.;Christopher C Striebich.;Maria Dall'era.;Meggan Mackay.;Ewa Olech.;Tracy Frech.;Jane Box.;Richard Keating.;Mary Chester Wasko.;William St Clair.;Alan Kivitz.;Weiquang Huang.;PetaGay Ricketts.;Beverly Welch.;Sherrie Callahan.;Meagan Spychala.;Karen Boyle.;Kate York.;Lynette Keyes-Elstein.;Ellen Goldmuntz.;Betty Diamond.;Anne Davidson.
来源: Rheumatology (Oxford). 2020年59卷7期1505-1513页
3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors (statins) are standard treatment for hyperlipidaemia. In addition to lipid-lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives of this study were to determine whether treatment of patients with RA with lovastatin decreased CRP or reduced disease activity.
189. Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
作者: Ana-Maria Orbai.;Alexis Ogdie.;Laure Gossec.;William Tillett.;Ying Ying Leung.;Jingjing Gao.;Mona Trivedi.;Chantal Tasset.;Luc Meuleners.;Robin Besuyen.;Thijs Hendrikx.;Laura C Coates.
来源: Rheumatology (Oxford). 2020年59卷7期1495-1504页
To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life (HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in active PsA.
190. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.
作者: Désirée van der Heijde.;Philip J Mease.;Robert B M Landewé.;Proton Rahman.;Hasan Tahir.;Atul Singhal.;Elke Boettcher.;Sandra Navarra.;Xuan Zhu.;Gregory Ligozio.;Aimee Readie.;Shephard Mpofu.;Luminita Pricop.
来源: Rheumatology (Oxford). 2020年59卷6期1325-1334页
To evaluate the effect of secukinumab on radiographic progression through 52 weeks in patients with PsA from the FUTURE 5 study.
191. Role of good oral hygiene on clinical evolution of rheumatoid arthritis: a randomized study nested in the ESPOIR cohort.
作者: Xavier Mariette.;Elodie Perrodeau.;Christian Verner.;Xavier Struillou.;Nicolas Picard.;Thierry Schaeverbeke.;Arnaud Constantin.;Philippe Ravaud.;Philippe Bouchard.
来源: Rheumatology (Oxford). 2020年59卷5期988-996页
There is a relationship between RA and periodontal disease. We aimed to investigate if a good oral hygiene could improve activity of RA.
192. Nurse-led care is preferred over GP-led care of gout and improves gout outcomes: results of Nottingham Gout Treatment Trial follow-up study.
作者: Amy Fuller.;Wendy Jenkins.;Michael Doherty.;Abhishek Abhishek.
来源: Rheumatology (Oxford). 2020年59卷3期575-579页
To explore patient satisfaction, gout knowledge, medication adherence and flares among participants receiving nurse-led or general practitioner (GP)-led care of gout in the Nottingham Gout Treatment Trial phase-II (NGTT-II).
193. Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis.
作者: Isabel Mortimer.;Lesley-Anne Bissell.;Elizabeth M A Hensor.;Lukasz Kozera.;Sarah L Mackie.;Agata N Burska.;Jackie L Nam.;Helen Keen.;Edith Villeneuve.;Helena Donica.;Maya H Buch.;Philip G Conaghan.;Paul Emery.;Ann W Morgan.;Jacqueline Andrews.
来源: Rheumatology (Oxford). 2019年58卷9期1684-1686页 194. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
作者: Ronald F van Vollenhoven.;Sandra V Navarra.;Roger A Levy.;Mathew Thomas.;Amy Heath.;Todd Lustine.;Anthony Adamkovic.;James Fettiplace.;Mei-Lun Wang.;Beulah Ji.;David Roth.
来源: Rheumatology (Oxford). 2020年59卷2期281-291页
This extension study of the Phase III, randomized, placebo-controlled Belimumab International SLE Study (BLISS)-52 and BLISS-76 studies allowed non-US patients with SLE to continue belimumab treatment, in order to evaluate its long-term safety and tolerability including organ damage accrual.
195. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
作者: Josef S Smolen.;Ronald Pedersen.;Heather Jones.;Ehab Mahgoub.;Lisa Marshall.
来源: Rheumatology (Oxford). 2020年59卷1期153-164页
The structural consequences of flare after dose reduction/discontinuation of biologic DMARDs in patients with RA who achieve remission are unclear. We compared the incidence of radiographic progression in patients with RA who did and did not experience flare after etanercept (ETN) reduction/withdrawal.
196. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial.
作者: Iris L A Bodewes.;Jacques-Eric Gottenberg.;Cornelia G van Helden-Meeuwsen.;Xavier Mariette.;Marjan A Versnel.
来源: Rheumatology (Oxford). 2020年59卷1期107-111页
HCQ is frequently used to treat primary SS (pSS), but evidence for its efficacy is limited. HCQ blocks IFN activation, which is present in half of the pSS patients. The effect of HCQ treatment on the expression of IFN-stimulated genes (ISGs) was studied in pSS. Furthermore, HCQ-treated patients were stratified based on IFN activation and differences in disease activity and clinical parameters were studied.
197. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
作者: Veerle Stouten.;René Westhovens.;Sofia Pazmino.;Diederik De Cock.;Kristien Van der Elst.;Johan Joly.;Patrick Verschueren.; .
来源: Rheumatology (Oxford). 2019年58卷12期2284-2294页
To investigate whether MTX should be combined with an additional DMARD and bridging glucocorticoids as initial treatment for patients with early RA to induce an effective long-term response.
198. Responders to intradiscal glucocorticoid among patients with chronic low back pain and active discopathy.
作者: Charlotte Pauwels.;Camille Daste.;Serge Poiraudeau.;Marie-Martine Lefèvre-Colau.;François Rannou.;Christelle Nguyen.
来源: Rheumatology (Oxford). 2019年58卷9期1689-1690页 199. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
作者: Seung Cheol Shim.;Ljubinka Božić-Majstorović.;Alfredo Berrocal Kasay.;Elias Chalouhi El-Khouri.;Fedra Irazoque-Palazuelos.;Francisco Fidencio Cons Molina.;Francisco G Medina-Rodriguez.;Pedro Miranda.;Pavel Shesternya.;Jose Chavez-Corrales.;Piotr Wiland.;Slawomir Jeka.;Olena Garmish.;Pawel Hrycaj.;Natalia Fomina.;Won Park.;Chang-Hee Suh.;Sang Joon Lee.;Sung Young Lee.;Yun Ju Bae.;Dae Hyun Yoo.
来源: Rheumatology (Oxford). 2019年58卷12期2193-2202页
To evaluate the efficacy and safety of CT-P10, a rituximab biosimilar after a single switch, during a multinational, randomized, double-blind Phase 3 trial involving patients with RA.
200. Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients.
作者: Joost F Swart.;Sytze de Roock.;Rutger A J Nievelstein.;Ineke C M Slaper-Cortenbach.;Jaap J Boelens.;Nico M Wulffraat.
来源: Rheumatology (Oxford). 2019年58卷10期1812-1817页
To compare the total number of adverse events (AEs) before and after mesenchymal stromal cell (MSC) infusion in refractory JIA and to evaluate its effectiveness.
|